Accession Number: | 0001104659-20-078271 |
Date: | 2020-06-25 |
Issuer: | KALA PHARMACEUTICALS, INC. (KALA) |
Original Submission Date: |
BAZEMORE TODD
C/O KALA PHARMACEUTICALS, INC.
490 ARSENAL WAY, SUITE 120
WATERTOWN, MA 02472
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2020-06-25 | A | 19,000 | a | $0.00 | 29,000 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|
ID | footnote |
---|---|
f1 | grant of restricted stock units ("rsus") under the issuer's 2017 equity incentive plan. each rsu represents a contingent right to receive one share of the issuer's common stock. subject to the reporting person's continued employment with the issuer, the rsus will vest as to 50% of the shares underlying the rsus on june 25, 2021 and the remaining 50% of the shares underlying the rsus on june 25, 2022. |
f2 | includes 19,000 unvested rsus. |